NovaBay Pharmaceuticals, Inc. (NBY)
NYSEAMERICAN: NBY · Real-Time Price · USD
1.100
+0.020 (1.85%)
Nov 13, 2025, 4:00 PM EST - Market closed
NovaBay Pharmaceuticals Stock Forecast
Stock Price Forecast
There have not been any analyst price target forecasts for NovaBay Pharmaceuticals in the last 12 months.
Price Target: n/a
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for NovaBay Pharmaceuticals.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $8 → $0.85 | Strong Buy | Maintains | $8 → $0.85 | -22.73% | Nov 11, 2024 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $5,206 → $4,900 | Strong Buy | Maintains | $5,206 → $4,900 | +445,354.55% | May 20, 2022 |
| Roth Capital | Roth Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 26, 2018 |
| Roth Capital | Roth Capital | Strong Buy Initiates $193 | Strong Buy | Initiates | $193 | +17,400.00% | Jun 5, 2017 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Initiates $68,906 | Strong Buy | Initiates | $68,906 | +6,264,104.55% | Mar 6, 2013 |
Financial Forecast
Revenue This Year
12.12M
from 9.78M
Increased by 23.91%
Revenue Next Year
16.00M
from 12.12M
Increased by 32.05%
EPS This Year
-0.87
from -2.53
EPS Next Year
-0.38
from -0.87
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 |
|---|---|---|
| High | 12.6M | 16.6M |
| Avg | 12.1M | 16.0M |
| Low | 11.8M | 15.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 |
|---|---|---|
| High | 28.8% | 37.3% |
| Avg | 23.9% | 32.0% |
| Low | 20.2% | 28.1% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | -0.90 | -0.40 |
| Avg | -0.87 | -0.38 |
| Low | -0.84 | -0.37 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.